ATE451119T1 - Untereinheit-impfstoff gegen das respiratorische synzytialvirus - Google Patents
Untereinheit-impfstoff gegen das respiratorische synzytialvirusInfo
- Publication number
- ATE451119T1 ATE451119T1 AT04761567T AT04761567T ATE451119T1 AT E451119 T1 ATE451119 T1 AT E451119T1 AT 04761567 T AT04761567 T AT 04761567T AT 04761567 T AT04761567 T AT 04761567T AT E451119 T1 ATE451119 T1 AT E451119T1
- Authority
- AT
- Austria
- Prior art keywords
- synzytial
- subunity
- virus
- vaccine against
- against respiratory
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002134 immunopathologic effect Effects 0.000 abstract 2
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48780403P | 2003-07-15 | 2003-07-15 | |
| US56758604P | 2004-05-03 | 2004-05-03 | |
| US10/888,805 US7368537B2 (en) | 2003-07-15 | 2004-07-09 | Subunit vaccine against respiratory syncytial virus infection |
| PCT/CA2004/001007 WO2005007189A1 (en) | 2003-07-15 | 2004-07-14 | Subunit vaccine against respiratory syncytial virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE451119T1 true ATE451119T1 (de) | 2009-12-15 |
Family
ID=34084525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04761567T ATE451119T1 (de) | 2003-07-15 | 2004-07-14 | Untereinheit-impfstoff gegen das respiratorische synzytialvirus |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7368537B2 (enExample) |
| EP (2) | EP1651264B1 (enExample) |
| JP (1) | JP2007505033A (enExample) |
| AT (1) | ATE451119T1 (enExample) |
| AU (1) | AU2004257363A1 (enExample) |
| CA (1) | CA2532164A1 (enExample) |
| DE (1) | DE602004024542D1 (enExample) |
| ES (1) | ES2337901T3 (enExample) |
| WO (1) | WO2005007189A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1372706B1 (en) * | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| JP4966661B2 (ja) * | 2003-10-22 | 2012-07-04 | アイディー バイオメディカル コーポレイション オブ ケベック | 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法 |
| NZ578727A (en) * | 2004-06-25 | 2011-03-31 | Brigham & Womens Hospital | Proteosome compositions and methods for treating neurological disorders |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| KR20110045008A (ko) * | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
| WO2010075491A2 (en) * | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| US9566323B2 (en) * | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
| PL2445526T3 (pl) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Rekombinowane antygeny rsv |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| MX2012000372A (es) | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| US8846056B2 (en) * | 2009-08-04 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control | Anti-RSV immunogens and methods of immunization |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| US8730396B2 (en) * | 2010-06-23 | 2014-05-20 | MindTree Limited | Capturing events of interest by spatio-temporal video analysis |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| FI4005592T3 (fi) * | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
| CN106008716B (zh) | 2010-07-07 | 2019-08-13 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
| RS63890B1 (sr) * | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| JP5911870B2 (ja) * | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| KR20120068647A (ko) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | 개선된 면역반응을 유도하는 백신 |
| AU2012205315B2 (en) * | 2011-01-13 | 2017-05-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US10736844B2 (en) | 2011-01-13 | 2020-08-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| RU2456020C1 (ru) * | 2011-03-30 | 2012-07-20 | Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) | Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой |
| JP2014518620A (ja) * | 2011-04-26 | 2014-08-07 | モレキュラー エクスプレス,インコーポレイテッド | リポソーム製剤 |
| RS56748B1 (sr) | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| EP4008354A1 (en) | 2012-01-27 | 2022-06-08 | Variation Biotechnologies Inc. | Methods and compositions for therapeutic agents |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| SG11201500573RA (en) | 2012-08-06 | 2015-02-27 | Glaxosmithkline Biolog Sa | Method for eliciting in infants an immune response against rsv and b. pertussis |
| SG11201600709TA (en) | 2013-08-05 | 2016-02-26 | Glaxosmithkline Biolog Sa | Combination immunogenic compositions |
| US9415101B2 (en) * | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| KR101695518B1 (ko) * | 2014-09-30 | 2017-01-12 | 이화여자대학교 산학협력단 | 호흡기 신시치아 바이러스 범용 백신 |
| CA3004924A1 (en) | 2015-11-10 | 2017-05-18 | Ohio State Innovation Foundation | Methods and compositions related to accelerated humoral affinity |
| EP3694548A4 (en) * | 2017-10-13 | 2021-10-20 | Trellis Bioscience, LLC | CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS |
| WO2020033742A1 (en) | 2018-08-08 | 2020-02-13 | Trellis Bioscience, Llc | Improved rsv passive and active vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| PT854729E (pt) * | 1995-09-18 | 2004-08-31 | Us Army Med Res Mat Com Usamrm | Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente |
| US5848152A (en) | 1995-09-26 | 1998-12-08 | Motorola, Inc. | Communication device having interchangeable faceplates and active keypad cover |
| CA2302833C (en) | 1997-09-19 | 2007-05-08 | American Cyanamid Company | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
| US6699478B1 (en) * | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
| JP3980884B2 (ja) | 2000-02-15 | 2007-09-26 | アイディー バイオメディカル コーポレイション オブ ケベック | プロテオソーム・インフルエンザ・ワクチン |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| EP1372706B1 (en) * | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
-
2004
- 2004-07-09 US US10/888,805 patent/US7368537B2/en not_active Expired - Fee Related
- 2004-07-14 JP JP2006519734A patent/JP2007505033A/ja active Pending
- 2004-07-14 DE DE602004024542T patent/DE602004024542D1/de not_active Expired - Lifetime
- 2004-07-14 ES ES04761567T patent/ES2337901T3/es not_active Expired - Lifetime
- 2004-07-14 AT AT04761567T patent/ATE451119T1/de not_active IP Right Cessation
- 2004-07-14 WO PCT/CA2004/001007 patent/WO2005007189A1/en not_active Ceased
- 2004-07-14 AU AU2004257363A patent/AU2004257363A1/en not_active Abandoned
- 2004-07-14 EP EP04761567A patent/EP1651264B1/en not_active Expired - Lifetime
- 2004-07-14 EP EP09178294A patent/EP2204188A1/en not_active Withdrawn
- 2004-07-14 CA CA002532164A patent/CA2532164A1/en not_active Abandoned
-
2008
- 2008-03-19 US US12/051,397 patent/US20080226673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2204188A1 (en) | 2010-07-07 |
| AU2004257363A1 (en) | 2005-01-27 |
| EP1651264A1 (en) | 2006-05-03 |
| US20080226673A1 (en) | 2008-09-18 |
| JP2007505033A (ja) | 2007-03-08 |
| WO2005007189A1 (en) | 2005-01-27 |
| DE602004024542D1 (de) | 2010-01-21 |
| CA2532164A1 (en) | 2005-01-27 |
| US20050042230A1 (en) | 2005-02-24 |
| US7368537B2 (en) | 2008-05-06 |
| EP1651264B1 (en) | 2009-12-09 |
| ES2337901T3 (es) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004024542D1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| WO2004060308A3 (en) | Thiosemicarbazones as anti-virals and immunopotentiators | |
| CY2013026I1 (el) | Πολυπεπτιδιου-εμβολια για ευρεια προστασια εναντι υπερ-λοιμογονων μηνιγγιοκοκκικων γενεαλογικων σειρων | |
| CY2016018I1 (el) | Εμβολιο κατα του ιου του δυτικου νειλου | |
| DK1409692T3 (da) | Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine | |
| ATE553775T1 (de) | Impstoffzusammesetzung | |
| ATE485056T1 (de) | Verbesserte impfstoffe | |
| WO2004030608A3 (en) | Nanoemulsion vaccines | |
| DE60328481D1 (de) | Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält | |
| CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
| EP1307130A4 (en) | VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS | |
| DK1427444T3 (da) | West-nil-vaccine | |
| ATE452900T1 (de) | Impfstoff gegen das west-nile-virus | |
| EP1423141A4 (en) | VACCINE | |
| NO20033882D0 (no) | Vaksine | |
| NO20052149D0 (no) | Vaksine. | |
| DE60130998D1 (de) | Ribavirin-enthaltende vakzine | |
| ATE269104T1 (de) | Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert | |
| WO2004091524A3 (en) | Respiratory virus vaccines | |
| ATE518012T1 (de) | Isolate des das reproduktions- und atemwegssyndrom verursachenden schweinevirus und ihre verwendung | |
| EA200301151A1 (ru) | Вакцина против натуральной оспы | |
| ATE380557T1 (de) | E. coli vakzin zur protektion von geflügel gegen colibazillose | |
| ATE392903T1 (de) | Impfstoff gegen pferdeherpesvirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |